HPV Vaccines
Recombinant virus-like particle vaccines
This page catalogs 4 human papillomavirus (HPV) vaccine products. All HPV vaccines use recombinant virus-like particle (VLP) technology — self-assembling protein structures that mimic the virus surface but contain no viral genetic material. HPV vaccination targets cancer-causing HPV types and is recommended as part of routine adolescent immunization in the United States and many countries worldwide.
Last updated: April 2026.
HPV Vaccine Catalog
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| Gardasil | HPV quadrivalent (6, 11, 16, 18) vaccine | Merck | Recombinant VLP | FDA Licensed, 2006 | First HPV vaccine; superseded by Gardasil 9 |
| Gardasil 9 | HPV 9-valent vaccine | Merck | Recombinant VLP | FDA Licensed, 2014 | Current standard; covers 9 HPV types |
| Cervarix | HPV bivalent (16, 18) vaccine | GSK | Recombinant VLP + AS04 | FDA Licensed, 2009 | GSK bivalent; less used in US after Gardasil 9 |
| Cervavac | HPV quadrivalent vaccine | Serum Institute of India | Recombinant VLP | Licensed in India, 2022 | India-developed affordable HPV vaccine |
Sources
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026) and India DCGI records. Catalog scope informed by Khan, Shaz, The Ultimate Vaccine Timeline.